Literature DB >> 8712873

Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis.

C Jorgensen1, M C Picot, C Bologna, J Sany.   

Abstract

OBJECTIVE: To investigate the influence of breast feeding, use of the oral contraceptive pill (OCP), and parity on rheumatoid arthritis (RA).
METHODS: One hundred and seventy six women with RA were compared with 145 control subjects; all had at least one child. RA patients were classified as having severe (n = 82) or mild disease (n = 89) according to clinical joint evaluation, radiological score, biological inflammation, and the presence of HLA-DR1 or -DR4 alleles.
RESULTS: The mean age of RA patients was 58 years, and the mean age at the time of diagnosis of RA was 46 years. The mean time between onset of RA and the first birth was 23.6 (SD 3.8) years. The OCP user rates were 33% in the RA group and 47.6% in the control group (p < 0.02). OCP use was related to the mother's year of birth. The relative risk for developing RA was 0.598 (95% confidence interval (CI) 0.33 to 1.1) in women who had used OCP for more than five years compared with those who had never used OCPs. In contrast, the age at which the first pregnancy occurred, the number of children breast fed, and the duration of breast feeding were comparable in RA patients and healthy subjects. Among the RA patients, parity, duration of breast feeding, and the number of breast fed children were significantly increased in those with severe disease. Having more than three children increased the risk of developing severe disease 4.8-fold when adjusted for age and OCP use. Forty six percent of women with severe RA had a history of breast feeding duration greater than six months before disease onset, compared with 26% of patients with mild disease (p < 0.008). Having more than three breast fed children increased the risk of poor disease prognosis 3.7-fold. In contrast, OCP use had a protective role in the course of RA (44% of RA patients with mild disease were OCP users, compared with 21.7% of those with severe RA; p < 0.001). Among those using OCP for more than five years, the relative risk of developing severe disease was 0.1 (95% CI 0.01 to 0.6), after adjustment for age, parity, and breast feeding.
CONCLUSION: Our results suggest that parity, and to a lesser extent breast feeding, before RA onset worsened RA prognosis, whereas OCP use had a protective role. Prolactin and oestrogen may have a role in these effects.

Entities:  

Keywords:  Antibodies; Autoantibodies; Biology; Breast Feeding; Case Control Studies; Contraception; Contraceptive Methods; Demographic Factors; Developed Countries; Europe; Family Planning; Fertility; Fertility Measurements; France; Health; Immunity; Immunologic Factors; Infant Nutrition; Mediterranean Countries; Nutrition; Oral Contraceptives; Parity; Physiology; Population; Population Dynamics; Research Methodology; Research Report; Rheumatoid Factor; Risk Factors; Skeletal Effects; Studies; Western Europe

Mesh:

Substances:

Year:  1996        PMID: 8712873      PMCID: PMC1010101          DOI: 10.1136/ard.55.2.94

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  21 in total

1.  Pregnancy and the risk of developing rheumatoid arthritis.

Authors:  J M Hazes; B A Dijkmans; J P Vandenbroucke; R R de Vries; A Cats
Journal:  Arthritis Rheum       Date:  1990-12

2.  Diminished incidence of severe rheumatoid arthritis associated with oral contraceptive use.

Authors:  D van Zeben; J M Hazes; J P Vandenbroucke; B A Dijkmans; A Cats
Journal:  Arthritis Rheum       Date:  1990-10

3.  The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis.

Authors:  T D Spector; M C Hochberg
Journal:  J Clin Epidemiol       Date:  1990       Impact factor: 6.437

4.  The pill, parity, and rheumatoid arthritis.

Authors:  T D Spector; E Roman; A J Silman
Journal:  Arthritis Rheum       Date:  1990-06

5.  Presence of estrogen-binding sites on macrophage-like synoviocytes and CD8+, CD29+, CD45RO+ T lymphocytes in normal and rheumatoid synovium.

Authors:  M Cutolo; S Accardo; B Villaggio; P Clerico; M Bagnasco; D A Coviello; G Carruba; M lo Casto; L Castagnetta
Journal:  Arthritis Rheum       Date:  1993-08

Review 6.  Modulation of the immune response by the neuro-endocrine axis in rheumatoid arthritis.

Authors:  C Jorgensen; J Sany
Journal:  Clin Exp Rheumatol       Date:  1994 Jul-Aug       Impact factor: 4.473

7.  Bromocriptine suppresses postpartum exacerbation of collagen-induced arthritis.

Authors:  A Whyte; R O Williams
Journal:  Arthritis Rheum       Date:  1988-07

8.  Breast feeding, other reproductive factors and rheumatoid arthritis. A prospective study.

Authors:  J G Brun; S Nilssen; G Kvåle
Journal:  Br J Rheumatol       Date:  1995-06

9.  Breast-feeding and the onset of rheumatoid arthritis.

Authors:  P Brennan; A Silman
Journal:  Arthritis Rheum       Date:  1994-06

Review 10.  Rheumatoid arthritis and pregnancy.

Authors:  G L Klipple; F A Cecere
Journal:  Rheum Dis Clin North Am       Date:  1989-05       Impact factor: 2.670

View more
  19 in total

1.  Improved performance of epidemiologic and genetic risk models for rheumatoid arthritis serologic phenotypes using family history.

Authors:  Jeffrey A Sparks; Chia-Yen Chen; Xia Jiang; Johan Askling; Linda T Hiraki; Susan Malspeis; Lars Klareskog; Lars Alfredsson; Karen H Costenbader; Elizabeth W Karlson
Journal:  Ann Rheum Dis       Date:  2014-03-31       Impact factor: 19.103

Review 2.  Environmental and gene-environment interactions and risk of rheumatoid arthritis.

Authors:  Elizabeth W Karlson; Kevin Deane
Journal:  Rheum Dis Clin North Am       Date:  2012-05-30       Impact factor: 2.670

3.  The association between gravidity and primary biliary cirrhosis.

Authors:  Arti Parikh-Patel; Ellen Gold; Jessica Utts; M Eric Gershwin
Journal:  Ann Epidemiol       Date:  2002-05       Impact factor: 3.797

4.  Disease progression in relation to pre-onset parity among women with rheumatoid arthritis.

Authors:  Tiffany D Pan; Beth A Mueller; Carin E Dugowson; Michael L Richardson; J Lee Nelson
Journal:  Semin Arthritis Rheum       Date:  2019-06-18       Impact factor: 5.532

5.  Is the incidence of rheumatoid arthritis rising?: results from Olmsted County, Minnesota, 1955-2007.

Authors:  Elena Myasoedova; Cynthia S Crowson; Hilal Maradit Kremers; Terry M Therneau; Sherine E Gabriel
Journal:  Arthritis Rheum       Date:  2010-06

6.  Association of environmental and genetic factors and gene-environment interactions with risk of developing rheumatoid arthritis.

Authors:  Elizabeth W Karlson; Bo Ding; Brendan T Keenan; Katherine Liao; Karen H Costenbader; Lars Klareskog; Lars Alfredsson; Lori B Chibnik
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-07       Impact factor: 4.794

7.  Geographic variation in rheumatoid arthritis incidence among women in the United States.

Authors:  Karen H Costenbader; Shun-Chiao Chang; Francine Laden; Robin Puett; Elizabeth W Karlson
Journal:  Arch Intern Med       Date:  2008-08-11

8.  Comparison of threshold cutpoints and continuous measures of anti-cyclic citrullinated peptide antibodies in predicting future rheumatoid arthritis.

Authors:  Lori B Chibnik; Lisa A Mandl; Karen H Costenbader; Peter H Schur; Elizabeth W Karlson
Journal:  J Rheumatol       Date:  2009-02-17       Impact factor: 4.666

9.  Contributions of familial rheumatoid arthritis or lupus and environmental factors to risk of rheumatoid arthritis in women: a prospective cohort study.

Authors:  Jeffrey A Sparks; Chia-Yen Chen; Linda T Hiraki; Susan Malspeis; Karen H Costenbader; Elizabeth W Karlson
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-10       Impact factor: 4.794

Review 10.  The role of the prolactin/vasoinhibin axis in rheumatoid arthritis: an integrative overview.

Authors:  Carmen Clapp; Norma Adán; María G Ledesma-Colunga; Mariana Solís-Gutiérrez; Jakob Triebel; Gonzalo Martínez de la Escalera
Journal:  Cell Mol Life Sci       Date:  2016-03-29       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.